Search Results for "CT P6 Celltrion"

22:19 EST 1st December 2015 | BioPortfolio

Matching Channels


Matching News

Celltrion, Inc. - Product Pipeline Review - 2015

Celltrion, Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘Celltrion, Inc. - Product Pipeline Review - 2015’, provides an overview of the Celltrion, Inc.’s pharmaceutic...

Hospira/Celltrion: Don't Let U.S. Biosimilar Law's Questions 'Percolate'

"Further percolation will not advance the law," Hospira and Celltrion said, insisting that "settling the issue will spur competition."

Remsima's US FDA review held back by contradictory demands, says Celltrion

Contradictory requests from the US FDA on the statistical analysis of Remsima are one of many regulatory hurdles facing biosimilar developers, according to Celltrion.

Celltrion submits rituximab biosimilar application to EMA

South Korean biotechnology company Celltrion has, according to Business Korea, submitted a second biosimilar application to the European Medicines Agency (EMA).

Celltrion seeks EU approval for rituximab biosimilar

Korean drugmaker Celltrion filed for approval from the European Medicines Agency for CT-P10, a biosimilar for the monoclonal  -More- 

Celltrion gains Russian approval for Remsima

South Korea’s Celltrion has received approval to sell its Remsima from the Ministry of Health of the…

Biosimilar Launch Notification: Celltrion Claims Loophole In Remicade Suit

Celltrion contends that since it provided its infliximab biosimilar application to Janssen it doesn’t have to wait until FDA approval to provide 180-day notice of commercial launch.

Data for Celltrion’s biosimilar infliximab CT-P13 presented at EULAR 2015

Data presented at EULAR 2015 show that the effectiveness of Celltrion’s biosimilar infliximab was similar to the RMP in rheumatoid arthritis... The post Data for Celltrion’s biosimilar infliximab ...

Matching PubMed Articles


Search Whole site using Google


Advertisement Advertisement